Health and Happiness (H&H) International Holdings Limited Overview
H&H Group is a Hong Kong-listed, China-centric premium family nutrition company. It has repositioned from a single-category Chinese infant formula and probiotics player (Biostime) into a three-pillar global portfolio:
Adult Nutrition & Care (ANC): Swisse, the No. 1 VHMS brand in both Chinese mainland and Australia.
Baby Nutrition & Care (BNC): Biostime super-premium infant milk formula (IMF), paediatric probiotics and supplements.
Pet Nutrition & Care (PNC): Zesty Paws and Solid Gold, anchored in the US.
The business model is asset-light: brand, formulation, regulatory licensing and channel orchestration, with predominantly outsourced manufacturing. It has structurally high gross margins of 60–65% but heavy advertising and promotion intensity of about 38–42% of revenue. The investment case turns on three things:
-
whether the 2025–26 recovery in Biostime IMF share is durable, helped in 2026 by competitor recalls;
-
whether Swisse can keep growing in China's cross-border and Douyin channels;
-
whether management can complete the deleveraging begun after the debt-funded US$610M Zesty Paws acquisition. Net leverage fell from 3.99x at end-2024 to 2.05x at 30 June 2026.
Company's own description (FY2025 annual results, Note 1): The Group is "principally engaged in the manufacture and sale of premium paediatric nutrition, baby care products, adult nutrition and care products and pet nutrition and care products." The Chairman's framing since 2023 is to become "a global leader in premium family nutrition and wellness with superior products and aspirational brands." B Lab (2024) summarises the mission as making millions of people and their pets healthier and happier.
Independent characterisation. H&H is best understood as a branded consumer-health platform with three economically distinct engines:
-
ANC (48.4% of FY2025 revenue). A VHMS (vitamins, herbal and mineral supplements) franchise built on the Swisse brand, acquired in 2015.
-
About 70.7% of ANC revenue comes from Chinese mainland (FY2025). Roughly 82% of that is sold through cross-border e-commerce (CBEC), with the balance through "blue hat"-registered normal trade.
-
The Australian domestic market is about 11% of group revenue.
-
Thirteen expansion markets (Singapore, Hong Kong, Italy, Thailand, Malaysia, Indonesia, India, the Middle East and others) contributed 6.9% of ANC sales in FY2025 and 7.8% in H1 2026.
-
This is the highest-margin engine: segment gross margin was 67.9% in FY2025 and 70.2% in H1 2026.
-
-
BNC (36.6% of FY2025; 41.8% of H1 2026). Biostime super-premium IMF (mostly imported French-made formulas, including goat-milk and organic), paediatric probiotics (No. 1 in China), kids' nutritional supplements, and residual baby food and care (Good Goût, Dodie).
-
Revenue is overwhelmingly Chinese mainland (97% of FY2025 IMF revenue), sold through mother-and-baby specialty stores, e-commerce and Douyin.
-
This engine is exposed to China's birth-rate decline and to the SAMR "new GB" registration regime, which required re-registration of every IMF series by 2023. H&H completed its transition by June 2025.
-
-
PNC (15.0% of FY2025). Zesty Paws, a multi-condition pet supplement brand and the high-margin growth driver, and Solid Gold, a holistic pet food brand being premiumised.
-
North America is 80% of PNC revenue (FY2025), sold through Amazon, Chewy, Walmart, PetSmart, Petco, Tractor Supply, Target and others.
-
Chinese mainland PNC is being restructured toward locally made, higher-margin product.
-
Revenue model. Revenue is 100% product sales ("sale of goods", recognised at a point in time). There is no material service, subscription or licensing revenue. Mainland China business customers usually pay in advance; overseas customers receive 30–90 day credit terms. Sales rebates and returns create variable consideration (refund liabilities of RMB635.9M at 30 June 2026). No single customer exceeds 10% of revenue.
Value chain position. H&H sits at the brand-owner and marketer layer:
Upstream: formulation, R&D and clinical substantiation (R&D is only 1.2–1.9% of revenue), regulatory registration (China GB formula registration, blue-hat health food licences, cross-border filings), and procurement of ingredients and contract manufacturing. Key IMF supply comes from French dairy partners, including Isigny Sainte Mère (ISM), in which H&H holds an investment.
Downstream: omni-channel distribution (CBEC platforms Tmall Global and JD International, Douyin, Sam's Club, baby specialty stores, pharmacies, Australian grocery and pharmacy, US pet specialty and mass retail).
- PP&E is only RMB302.8M against total assets of RMB19.4bn (FY2025). Goodwill and intangibles are RMB12.7bn, or 65% of total assets.
Customer types and end-markets.
-
End consumers: Chinese urban middle-class parents (IMF/probiotics), health-conscious adults and ageing consumers (VHMS, NAD+, cellular nutrition, heart and liver health), and pet parents (US, China).
-
Trade customers: e-commerce platforms, distributors, mother-and-baby chains, pharmacy chains, grocery, pet specialty and mass merchandisers.
-
End-markets: China IMF (about RMB185bn in 2025 per Daxue Consulting, cited by Reuters), China VHMS, Australian VMS, US pet supplements and pet food.
Strategy
Stated strategic themes
FY2023 strategic objectives (Chairman's Statement):
-
Drive growth in high-margin nutritional supplements.
-
Maintain healthy profitability and share in super-premium IMF.
-
Win in core markets: ANC in China and ANZ, PNC in North America.
-
Invest in the future by expanding into new markets.
-
Optimise the capital structure.
FY2022 framing: "Winning in Core, Globalisation and Diversification, and Investing in the Future," plus the "PPAE" brand model (Premium, Proven, Aspirational, Engaging).
FY2025 / 2026 outlook themes:
-
Grow high-margin, fast-growing nutritional supplements while delivering healthy profitability.
-
Consolidate Swisse's No. 1 position in China.
-
Prioritise Douyin and new retail channels.
-
Scale the thirteen expansion markets using the Singapore and Hong Kong playbook.
-
Sustain IMF momentum through new-mother education and Stage 3 conversion, and extend into broader children's nutrition.
-
Lift Solid Gold's high-margin mix above 37%.
-
Complete China pet supply localisation by end-2026.
-
Continue deleveraging and raise the share of RMB debt.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail / target |
|---|---|---|
| Group-wide B Corp certification | Oct 2024 | Score 92.5; achieved ahead of the 2025 target |
| Capital structure refinancing | Jan 2025 | US$300M 9.125% senior notes due 2028 replaced the 13.5% notes due 2026 |
| Corporate daigou deprioritisation | Mid-2025 | Strategic exit from a low-quality export channel in ANZ |
| New-GB IMF transition complete | Jun 2025 | All series relaunched under new GB |
| Douyin / new-retail channel push | 2025–26 | Douyin +71.4% (2025), +57.5% (H1 2026); Sam's Club +29.7% / +34.2% |
| Swisse Plus cellular nutrition and Little Swisse "mega-brand" | 2025–26 | Swisse Plus +18.6%; Little Swisse +60.2% (H1 2026) |
| Swisse Nutra (premium beauty) launch | H1 2026 | Asia expansion markets |
| Biostime HMO IMF launch | H1 2026 | Described as the first imported HMO IMF in China; H2 2026 marketing step-up |
| Solid Gold China supply localisation | 2025–end-2026 | Response to US–China tariffs |
| Solid Gold US premiumisation and channel optimisation | Completed 2025 | High-margin mix about 37%; returned to growth in H1 2026 |
| European restructuring (Good Goût / Dodie) | 2,025 | RMB29.8M one-time costs; RMB106.5M impairment |
| Group entity structure optimisation | 2024–25 | One-time consulting fees of RMB17.0M (2024) and RMB19.8M (2025) |
| Debt reduction | 2025–26 | Gross debt down more than RMB600M (2025) and more than RMB1bn (H1 2026); about RMB1.2bn of USD term-loan prepayments in H1 2026 and RMB300M on 13 Aug 2026; RMB / RMB-hedged debt at 97.8% of borrowings (Jun 2026) |
| Term loan refinancing | 5 Aug 2026 | About US$320M term loan plus a US$10M RCF to refinance 2027 maturities |
| Dividend policy reset upward | Aug 2026 | Interim payout 50% of adjusted net profit (vs 30% for FY2025) |
Medium-term targets and guidance
-
No numeric multi-year revenue or margin targets are disclosed by the company.
-
Qualitative 2026 guidance: "continued growth with consistent underlying full-year profitability despite macro challenges", with higher H2 2026 marketing investment.
-
Historical dividend policy: about 50% of adjusted net profit (stated in FY2022), lowered to about 30% for FY2024–25 during deleveraging, and returned to 50% at the 2026 interim.
-
Historical aspiration: a 2023 China revenue target of RMB10bn (cut from an earlier RMB20bn aspiration, per Jiemian media). This is not a current formal target.
Products & Services
Pricing models: all products are sold at retail and wholesale list prices. List prices and price architecture are not publicly disclosed in filings, so SKU-level pricing is "not publicly disclosed" unless noted.
ANC — Adult Nutrition & Care
| Brand / line | Description and capabilities | Target customer | Launch / latest | Flagships and notes |
|---|---|---|---|---|
| Swisse (Core) | Australian-origin VHMS: multivitamins, beauty-from-within (hair/skin/nails), liver detox (milk thistle), heart health, joint health, immunity, sleep and stress, magnesium | Mass-premium adults, China and ANZ | Acquired 2015; continuous NPD | Swisse Liver Cleanse leads the high-end milk thistle segment in China e-commerce (FY2023). Swisse Magnesium Glycinate is a 2025 ANZ hit. Swisse revenue reached US$1bn net sales in FY2025 (company). No. 1 in China overall VHMS (Kantar, FY2025) and No. 1 Australia VMS (IQVIA) |
| Swisse Plus / Plus+ | Premium "cellular nutrition" and anti-ageing tier: NAD+ range, metabolism, heart health | Ageing, affluent consumers (China) | 2022 (NAD+), expanding | NAD+ ranked No. 2 in China e-commerce NAD+ (Early Data, 2023). Double-digit share of China ANC revenue (2023). +18.6% growth in H1 2026 |
| Little Swisse | Kids' supplements, including Kids Gummies | Parents of children aged 3+ | c.2023; ANZ Kids Gummies 2025 | +60.2% in H1 2026 |
| Swisse Me | Functional food and snack-format nutrition for Gen Z | Young adults (China) | 2,022 | Disclosed as popular with Gen Z (FY2022) |
| Swisse Gummies | Sugar-free gummy formats | ANZ and expansion markets | 2022–23 | No. 2 position in ANZ gummies (FY2023) |
| Swisse Nutra | Premium beauty supplement range | Expansion markets (Asia) | H1 2026 | New launch cited in H1 2026 |
| Swisse Earth | Range with packaging of up to 70% recycled content | ANZ eco-conscious consumers | c.2022 | ESG-led line |
| Sports nutrition / skin care | Included in the ANC segment definition | Adults | — | Aurelia skincare discontinued in the UK (FY2024 restructuring) |
Channel facts:
China, FY2025: CBEC was 82.0% of China ANC revenue. Douyin grew +71.4% (Swisse ranked No. 4), and Sam's Club grew +29.7%.
China, H1 2026: CBEC was 81.7% with +20.9% growth. Douyin grew +57.5% (Swisse now No. 3), and new retail grew +34.2%.
BNC — Baby Nutrition & Care
| Brand / line | Description | Target | Launch / latest | Flagships and notes |
|---|---|---|---|---|
| Biostime super-premium IMF (Stages 1–3) | Imported French-made cow-milk IMF series registered under new GB | Chinese urban parents, premium/super-premium | New-GB series approved Feb–Dec 2023; transition complete Jun 2025 | Alpha Star was the first new-GB approval (Feb 2023); seven series approved by Dec 2023. Super-premium share: 12.1% (2022), 12.4% (2023), 13.3% (2024), 17.1% (2025), 20.6% LTM Jun 2026 (Nielsen) |
| Biostime HMO IMF | Described as the first imported IMF with Human Milk Oligosaccharide in Chinese mainland | Premium parents | Rolled out H1 2026 | Key 2026 growth driver; marketing step-up in H2 2026 |
| Biostime goat-milk IMF | Imported goat-milk formula | Premium niche | Pending new-GB in 2023 (RMB178.6M write-off) | France pharmacy goat-milk share 57.9% (GERS, LTM Jun 2026) |
| Biostime organic IMF (France) | Organic formula sold in French pharmacies | French parents | Ongoing | France organic IMF pharmacy share 41.8% (LTM Jun 2026) |
| Biostime paediatric probiotics | Probiotic sachets, powders, capsules for infants, children and expectant mothers; lactoferrin probiotics; Nasal Comfort; Super Gold Probiotics | Parents (pharmacy, baby stores, online) | Since 1999; continuous NPD | No. 1 in China paediatric probiotics (Kantar). Online contribution rose from 49.2% (2024) to 62.1% (2025) |
| Biostime kids nutritional supplements | DHA, calcium, gummies, kids nutrition powder supplements | Children | 2022–2025 launches | Kids Gummies launched in China and France (2022) |
| Good Goût | French organic baby food and snacks | European parents | Acquired c.2018 | Impairments: RMB97.3M (2023, with Aurelia), part of RMB124.0M (2024), RMB106.5M (2025). European restructuring in 2025 |
| Dodie | French baby accessories and care (bottles, pacifiers); formerly diapers in China | Parents | China diaper business exited from 2024 | Part of the 2024 impairment |
PNC — Pet Nutrition & Care
| Brand / line | Description | Target | Launch / latest | Flagships and notes |
|---|---|---|---|---|
| Zesty Paws | Multi-condition dog and cat supplements (soft chews, oral sticks, powders, fish oil, probiotics, joint and hip, skin and coat, allergy/immune, calming); NASC-certified | US pet parents, premium | Brand founded 2014/15; acquired Oct 2021 | No. 1 on Amazon (2023); No. 4 offline, 10.0% share (2023). Growth: +21.7% (2023), +12.8% (2025), +16.7% LFL (H1 2026). Distribution in more than 23,000 US stores (Jun 2026). Channels include TikTok Shop. Fish-oil launch in China (2023); pilot in UK |
| Solid Gold | Holistic, super-premium dog and cat food (dry, wet, NutrientBoost range, toppers, bone broth), now expanding into supplements | Premium pet owners, US and China | Acquired Dec 2020 | US: channel optimisation completed 2025; returned to +6.3% LFL growth in H1 2026; e-commerce 83.1% of US sales; high-margin items 37.4% of sales (2025). China: No. 2 in online premium cat dry food; shifting to locally made supply (completion expected end-2026); first "cat-derived" probiotics range in China (H1 2026). In more than 4,000 US stores |
Financial Narrative
All figures are in RMB M under IFRS, from audited annual results announcements unless noted. Operating income is defined here as profit before tax + finance costs + share of losses of associates (derived).
Income statement
Revenue CAGR FY2021–FY2025: 5.6% (derived).
Adjusted EBITDA CAGR: 2.6%.
DPS composition (HKD): - FY2021: interim 0.37 + final 0.17
-
FY2022: 0.25 + 0.38
-
FY2023: 0.44 + 0.18
-
FY2024: 0.30 + 0.05
-
FY2025: 0.19 + 0.16
Commentary on income-statement trends.
FY2021–22: the Zesty Paws step-change: FY2021 reported profit halved (net profit RMB508.5M vs RMB1,136.7M in FY2020). The drivers were RMB361.7M of non-cash losses (FX, derivative fair value, Changsha goodwill impairment) and M&A costs; adjusted net profit fell a more modest 12.4%. FY2022 revenue rose 10.6% as Zesty Paws was consolidated (North America +144.5%), but finance costs nearly doubled to RMB525.7M on US$550M of incremental acquisition debt. This began a three-year period in which interest absorbed most of EBIT.
FY2023: mix shift masks the IMF crisis: ANC surged 34.8% on post-COVID immunity demand and Swisse Plus+, while BNC fell 11.7% as China's IMF market contracted 22.9% during the new-GB transition. Adjusted EBITDA peaked at RMB2,215.5M (15.9% margin). Finance costs jumped to RMB773.5M as US base rates rose. Net current liabilities of RMB3.3bn (refinancing wall) required a going-concern statement.
FY2024: the trough: BNC fell a further 25.8%. IMF fell 24.2% as old-GB stock destocked and new products launched, with RMB178.4M of one-time launch marketing. Probiotics fell 32.3% on pharmacy-channel weakness. Goodwill and intangible impairments (Dodie, Good Goût) of RMB124.0M and FX losses of RMB176.8M pushed the reported result to a RMB53.7M loss, despite adjusted net profit of RMB541.2M.
FY2025: recovery: Revenue grew +10.0% (IMF +26.5%) and gross margin expanded 180bps to 62.4% on sourcing optimisation and PNC mix. However, the S&D ratio rose to 42.2% (ANC channel mix toward Douyin and expansion-market investment), compressing adjusted EBITDA margin to 14.3%. Reported net profit of RMB196.1M was suppressed by a RMB224.4M one-time premium on early redemption of the 13.5% notes.
H1 2026: inflection: Operating leverage, a BNC demand surge partly from competitor recalls, marketing phasing and halved finance costs drove adjusted EBITDA margin to 21.8%. Management explicitly flagged higher H2 marketing for HMO IMF and Swisse launches, so H1 margins are not a full-year run-rate. The outlook speaks of "consistent underlying full-year profitability despite macro challenges."
Balance sheet
Notes:
-
FY2025 net debt (carrying) uses cash plus RMB40M of time deposits (RMB1,709.0M).
-
The company's net debt uses gross debt at constant FX rates as at drawdown.
-
FY2025 total debt comprises bank loans RMB6,079.9M, senior notes RMB2,158.6M, guaranteed bonds RMB410.8M and LC discounting RMB244.8M.
30 June 2026: borrowings RMB7,581.6M (current RMB1,803.0M); cash plus time deposits RMB1,976.5M; company net debt RMB5,813.7M; equity RMB6,513.8M; net current liabilities RMB783.9M. The current-liability position is driven by term loans due 2027 being reclassified as current; it is addressed by the US$320M refinancing signed on 5 Aug 2026.
Balance-sheet commentary.
-
Intangibles dominate. Goodwill and intangibles of RMB12.7bn exceed equity of RMB6.0bn by 2.1x, so tangible equity is negative. This is the structural legacy of the Swisse (2015), Solid Gold (2020) and Zesty Paws (2021) acquisitions.
-
Impairments to date have hit the smaller European assets (Aurelia, Good Goût, Dodie) and the Changsha plant, not the core brands.
-
The recurring "refinancing wall" pattern is notable: net current liabilities in FY2021 and FY2023, and again at H1 2026. Each was resolved, but it signals reliance on bank refinancing cycles.
-
Inventory discipline improved markedly: days fell from 169 (FY2021) to 129 (FY2025) and 118 (H1 2026).
-
The A$104M (RMB487.9M) ATO deposit sits in prepayments and deposits. It moved to non-current deposits (RMB509.6M) at June 2026.
Cash flow
Notes:
-
FY2022 capex includes right-of-use assets.
-
FY2025 OCF is after the RMB487.9M ATO deposit outflow. Excluding it, underlying OCF would be about RMB2.0bn (derived).
H1 2026: OCF RMB1,695.1M; capex RMB38.4M; cash conversion (pre-tax cash from operations / adjusted EBITDA) 100.0%.
Buybacks: no share cancellations in FY2021–H1 2026. The FY2022 HK$75.8M of purchases were for the share award trust. Debt buybacks: US$29.8M (2022) and US$68.2M (2023) of 5.625% 2024 notes, and US$20.2M (2023) and the full US$297M (2025) of 13.5% 2026 notes.
Ratios
Notes:
-
The FY2021 ROE denominator uses FY2020 equity of RMB6,202.7M.
-
The ROIC tax rate is a notional 30% (the reported ETR is distorted by non-deductible items). Invested capital uses carrying net debt.
-
Net leverage for FY2022 is shown as 3.58x per the FY2023 announcement's restated method. The FY2022 announcement originally reported 3.68x, a methodology discrepancy.
H1 2026: net leverage 2.05x (LTM adjusted EBITDA RMB2,841.7M); gearing (borrowings / total assets) 38.9%; CCC about 76 days (20 + 118 − 62); implied annual interest margin 5.65% (vs 6.96% FY2024 and 5.96% FY2025).
Ratio commentary.
-
Returns have been structurally modest (ROIC 6–9%) because of the large acquired-intangible base. The economic return on tangible capital is far higher, given RMB303M of PP&E.
-
The defining credit metric is interest coverage, which collapsed from about 4x to 1.2x between FY2021 and FY2024 as rates rose on floating USD term debt. It is now recovering sharply: H1 2026 EBIT of about RMB1,474M (derived) against finance costs of RMB311.9M is about 4.7x.
-
Working-capital efficiency has improved by about 40 days of CCC since FY2021.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business segment revenue (CNY Mn)
| Business segment revenue (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Adult Nutrition & Care (ANC) | 4,209.2 | 4,559.2 | 6,144.9 | 6,696.2 | 6,946.4 |
Baby Nutrition & Care (BNC) | 6,612.2 | 6,687.2 | 5,907.5 | 4,382.3 | 5,257.3 |
Pet Nutrition & Care (PNC) | 726.4 | 1,529.5 | 1,874.1 | 1,973.2 | 2,149.9 |
Group total | 11,547.8 | 12,775.9 | 13,926.5 | 13,051.7 | 14,353.6 |
Business segment YoY growth, reported (%)
| Business segment YoY growth, reported (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ANC | 8.3 | 34.8 | 9.0 | 3.7 |
BNC | 1.1 | -11.7 | -25.8 | 20.0 |
PNC | 110.6 | 22.5 | 5.3 | 9.0 |
Business segment share of revenue (%)
| Business segment share of revenue (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ANC | 36.4 | 35.7 | 44.1 | 51.3 | 48.4 |
BNC | 57.3 | 52.3 | 42.4 | 33.6 | 36.6 |
PNC | 6.3 | 12.0 | 13.5 | 15.1 | 15.0 |
Segment Overview
| Segment | H1 2026 revenue (CNY Mn) | YoY reported | YoY LFL | Share of revenue | Segment gross margin |
|---|---|---|---|---|---|
ANC | 3,973.1 | +15.5% | +13.9% | 45.7% | 70.2% |
BNC | 3,632.5 | +45.2% | +45.2% | 41.8% | 61.5% |
PNC | 1,090.3 | +1.0% | +4.8% | 12.5% | 61.1% |
Total | 8,695.9 | +23.9% | +23.7% | 100% | 65.4% |
Reportable segment revenue (CNY Mn)
| Reportable segment revenue (CNY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Infant formulas | 4,397.5 | 3,332.4 | 4,215.8 |
Paediatric probiotic & kids nutritional supplements | 1,213.3 | 821.3 | 837.3 |
Adult nutrition & care products | 6,144.9 | 6,696.2 | 6,946.4 |
Other paediatric products | 296.7 | 228.6 | 204.2 |
Pet nutrition & care products | 1,874.1 | 1,973.2 | 2,149.9 |
Reportable segment results = gross profit (CNY Mn)
| Reportable segment results = gross profit (CNY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Infant formulas | 2,301.5 | 1,849.2 | 2,323.2 |
Paediatric probiotic & kids nutritional supplements | 927.5 | 596.6 | 614.0 |
Adult nutrition & care products | 4,030.2 | 4,351.9 | 4,719.1 |
Other paediatric products | 123.7 | 99.7 | 78.4 |
Pet nutrition & care products | 911.4 | 1,018.1 | 1,228.9 |
Reportable segment gross margin (%)
| Reportable segment gross margin (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Infant formulas | 52.3 | 55.5 | 55.1 |
Paediatric probiotic & kids nutritional supplements | 76.4 | 72.6 | 73.3 |
Adult nutrition & care products | 65.6 | 65.0 | 67.9 |
Other paediatric products | 41.7 | 43.6 | 38.4 |
Pet nutrition & care products | 48.6 | 51.6 | 57.2 |
Reportable segment YoY growth (%)
| Reportable segment YoY growth (%) | FY2024 | FY2025 |
|---|---|---|
Infant formulas | -24.2 | 26.5 |
Paediatric probiotic & kids supplements | -32.3 | 2.0 |
Adult nutrition & care | 9.0 | 3.7 |
Other paediatric | -23.0 | -10.7 |
Pet nutrition & care | 5.3 | 9.0 |
Revenue by Segment (x)
| Segment contribution proxy (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ANC (GM minus S&D ratio) | 27.6 | 26.2 | 25.2 |
BNC (GM minus S&D ratio) | 18.1 | 14.2 | 17.6 |
PNC (GM minus S&D ratio) | 6.8 | 7.5 | 10.9 |
Income statement (CNY Mn)
| Income statement (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 11,547.8 | 12,775.9 | 13,926.5 | 13,051.7 | 14,353.6 |
Cost of sales | 4,299.8 | 5,072.4 | 5,632.2 | 5,136.2 | 5,389.9 |
Gross profit | 7,248.0 | 7,703.5 | 8,294.3 | 7,915.5 | 8,963.7 |
Selling & distribution expenses | 4,971.9 | 5,235.2 | 5,599.7 | 5,569.6 | 6,229.1 |
Administrative expenses | 695.7 | 727.7 | 848.5 | 779.4 | 837.3 |
Other expenses | 554.3 | 382.2 | 336.4 | 588.6 | 466.0 |
Operating income (derived EBIT) | 1,134.4 | 1,578.2 | 1,724.3 | 1,140.4 | 1,493.7 |
EBITDA (reported) | 1,428.9 | 1,847.9 | 1,984.9 | 1,405.8 | 1,772.6 |
Adjusted EBITDA (company) | 1,851.9 | 1,971.9 | 2,215.5 | 1,952.3 | 2,050.5 |
Finance costs | 285.1 | 525.7 | 773.5 | 920.6 | 909.9 |
Profit before tax | 850.2 | 1,030.9 | 933.6 | 196.8 | 563.1 |
Income tax expense | 341.7 | 419.1 | 351.8 | 250.5 | 367.0 |
Net profit (attributable) | 508.5 | 611.8 | 581.8 | -53.7 | 196.1 |
Adjusted net profit (company) | 952.9 | 731.2 | 778.3 | 541.2 | 664.1 |
EPS basic (MYR Bn) | 0.79 | 0.96 | 0.91 | -0.08 | 0.31 |
EPS diluted (MYR Bn) | 0.79 | 0.95 | 0.90 | -0.08 | 0.31 |
DPS total (HKD) | 0.54 | 0.63 | 0.62 | 0.35 | 0.35 |
Margins (%)
| Margins (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | 62.8 | 60.3 | 59.6 | 60.6 | 62.4 |
Operating (EBIT) margin | 9.8 | 12.4 | 12.4 | 8.7 | 10.4 |
EBITDA margin (reported) | 12.4 | 14.5 | 14.3 | 10.8 | 12.3 |
Adjusted EBITDA margin | 16.0 | 15.4 | 15.9 | 15.0 | 14.3 |
Net margin | 4.4 | 4.8 | 4.2 | -0.4 | 1.4 |
Adjusted net margin | 8.3 | 5.7 | 5.6 | 4.1 | 4.6 |
Effective tax rate (reported) | 40.2 | 40.7 | 37.7 | 127.3 | 65.2 |
Growth (%)
| Growth (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth, reported | 3.2 | 10.6 | 9.0 | -6.3 | 10.0 |
Revenue growth, LFL | — | 7.1 | 8.2 | — | 10.3 |
Adjusted EBITDA growth | -10.3 | 6.5 | 12.4 | -11.9 | 5.0 |
Income Statement and Per-Share Data
| H1 metric (CNY Mn) | H1 2025 | H1 2026 | Change |
|---|---|---|---|
Revenue | 7,019.2 | 8,695.9 | +23.9% |
Gross profit (GM) | 4,389.1 (62.5%) | 5,686.0 (65.4%) | +29.5% |
S&D expenses | 2,971.3 | 3,400.7 | +14.5% |
Finance costs | 579.5 | 311.9 | -46.2% |
Adjusted EBITDA (margin) | 1,100.7 (15.7%) | 1,891.9 (21.8%) | +71.9% |
Net profit | 71.0 | 610.6 | +760.0% |
Adjusted net profit | 363.0 | 919.2 | +153.2% |
EPS basic (MYR Bn) | 0.11 | 0.95 | — |
Interim DPS (HKD) | 0.19 | 0.82 | 50% of adjusted net profit |
Balance Sheet
| Balance sheet (CNY Mn, 31 Dec) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 20,281.7 | 20,963.0 | 20,042.0 | 18,842.4 | 19,403.5 |
Cash & cash equivalents | 2,400.1 | 2,303.7 | 1,364.3 | 1,603.9 | 1,669.0 |
Short-term debt (bank loans + notes, current) | 3,145.5 | 986.6 | 4,722.1 | 863.1 | 1,078.8 |
Long-term debt (bank loans + notes, non-current) | 6,229.8 | 8,581.6 | 4,393.4 | 8,421.8 | 7,815.3 |
Total debt (carrying) | 9,375.3 | 9,568.3 | 9,115.5 | 9,284.9 | 8,894.1 |
Net debt (carrying, derived) | 6,975.2 | 7,264.6 | 7,751.2 | 7,681.0 | 7,185.1 |
Net debt (company definition) | — | 7,059.8 | 7,569.4 | 7,799.4 | 7,081.2 |
Total equity | 5,885.2 | 6,141.9 | 6,295.2 | 5,813.4 | 5,990.9 |
Goodwill | 7,472.0 | 7,684.1 | 7,820.5 | 7,603.6 | 7,620.6 |
Intangible assets | 5,572.4 | 5,639.3 | 5,582.4 | 5,295.0 | 5,063.9 |
Goodwill + intangibles | 13,044.4 | 13,323.4 | 13,402.9 | 12,898.6 | 12,684.5 |
Inventories | 2,087.7 | 2,587.7 | 2,374.8 | 1,906.7 | 1,968.1 |
Working capital (current assets − current liabilities) | -1,308.5 | 724.5 | -3,307.8 | 750.3 | 680.9 |
Cash flow (CNY Mn)
| Cash flow (CNY Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Net operating cash flow | 1,469.3 | 1,096.9 | 1,346.4 | 1,536.8 |
Capex (PP&E + intangibles) | 102.5 | 91.0 | 97.3 | 94.4 |
Free cash flow (derived OCF − capex) | 1,366.8 | 1,005.9 | 1,249.1 | 1,442.4 |
Dividends paid | 233.6 | 474.5 | 281.9 | 141.5 |
Interest paid | 474.6 | 750.0 | 706.1 | 537.2 |
Share purchases (award-scheme trust) | 61.8 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%), net profit / average equity | 8.4 | 10.2 | 9.4 | -0.9 | 3.3 |
ROA (%), net profit / year-end assets | 2.5 | 2.9 | 2.9 | -0.3 | 1.0 |
ROIC (%), EBIT × (1 − 30%) / (equity + net debt) | 6.2 | 8.2 | 8.6 | 5.9 | 7.9 |
Current ratio (x) | 0.81 | 1.14 | 0.61 | 1.19 | 1.15 |
Debt / equity (x) | 1.59 | 1.56 | 1.45 | 1.60 | 1.48 |
Net debt / adjusted EBITDA (x, company) | 3.77 | 3.58 | 3.42 | 3.99 | 3.45 |
Interest coverage (x), EBIT / finance costs | 3.98 | 3.00 | 2.23 | 1.24 | 1.64 |
Adjusted EBITDA / finance costs (x) | 6.50 | 3.75 | 2.86 | 2.12 | 2.25 |
Asset turnover (x), revenue / year-end assets | 0.57 | 0.61 | 0.69 | 0.69 | 0.74 |
Receivable days (company) | 24 | 21 | 24 | 27 | 23 |
Inventory days (company) | 169 | 166 | 159 | 150 | 129 |
Payable days (company) | 64 | 79 | 76 | 68 | 64 |
Cash conversion cycle (days, derived) | 129 | 108 | 107 | 109 | 88 |
Geographic revenue (CNY Mn)
| Geographic revenue (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Chinese mainland | 9,084.6 | 9,565.9 | 9,972.7 | 8,685.4 | 10,201.5 |
Australia & New Zealand | 1,307.4 | 1,387.4 | 1,794.6 | 2,012.7 | 1,574.1 |
North America | 499.3 | 1,220.8 | 1,498.2 | 1,621.7 | 1,747.7 |
Other locations (incl. HK SAR, Europe, SE Asia) | 656.5 | 601.9 | 661.0 | 731.9 | 830.3 |
Geographic YoY growth, reported (%)
| Geographic YoY growth, reported (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Chinese mainland | 5.3 | 4.3 | -12.9 | 17.5 |
Australia & New Zealand | 6.1 | 29.4 | 12.2 | -21.8 |
North America | 144.5 | 22.7 | 8.2 | 7.8 |
Other locations | -8.3 | 9.8 | 10.7 | 13.4 |
Geographic share of revenue (%)
| Geographic share of revenue (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Chinese mainland | 78.7 | 74.9 | 71.6 | 66.6 | 71.1 |
Australia & New Zealand | 11.3 | 10.9 | 12.9 | 15.4 | 11.0 |
North America | 4.3 | 9.6 | 10.8 | 12.4 | 12.1 |
Other locations | 5.7 | 4.6 | 4.7 | 5.6 | 5.8 |
Region Overview
| Region | H1 2026 (CNY Mn) | YoY reported | YoY LFL | Share |
|---|---|---|---|---|
Chinese mainland | 6,462.5 | +30.9% | +30.9% | 74.3% |
North America | 956.6 | +10.9% | +15.5% | 11.0% |
ANZ | 771.7 | −3.6% | −8.6% | 8.9% |
Other | 505.1 | +20.2% | +16.8% | 5.8% |
Segment Overview — Infant formulas
| Segment | Chinese mainland | ANZ | North America | Other | Total |
|---|---|---|---|---|---|
Infant formulas | 4,091.3 | 18.5 | 0.0 | 106.0 | 4,215.8 |
Paediatric probiotics & kids supplements | 822.0 | 2.2 | 1.3 | 11.8 | 837.3 |
Adult nutrition & care | 4,911.7 | 1,553.2 | 24.8 | 456.7 | 6,946.4 |
Other paediatric | 0.8 | 0.0 | 0.0 | 203.3 | 204.2 |
Pet nutrition & care | 375.7 | 0.1 | 1,721.6 | 52.5 | 2,149.9 |
Total | 10,201.5 | 1,574.1 | 1,747.7 | 830.3 | 14,353.6 |
Share Price & Returns
| Reference point | Price (HKD) | Source |
|---|---|---|
14 Mar 2025 (Franklin sale price) | about 9.64 | Simply Wall St insider data |
22 Apr 2026 (close, approximate) | 13.82 | etnet |
Early Jul 2026 (post profit alert, intraday) | 12.48 → 14.65 | Tiger / Deep News |
8 Jul 2026 | 14.66 | Lixinger |
31 Jul 2026 | 15.19 | Lixinger |
5 Aug 2026 | 14.49 | Lixinger |
23 Sep 2026 | 17.95 | 10jqka (after Moody's outlook revision) |
Valuation Multiples
| Multiple | H&H | Basis |
|---|---|---|
Market cap | HK$11.59bn (about RMB10.26bn) | 645.56M shares |
P/E (TTM reported) | about 13.9x | TTM net profit RMB735.7M (FY2025 196.1 − H1'25 71.0 + H1'26 610.6) |
P/E (TTM adjusted) | about 8.4x | TTM adjusted net profit RMB1,220.3M |
EV / adjusted EBITDA (TTM) | about 5.7x | EV about RMB16.07bn (market cap + net debt RMB5,813.7M); LTM adjusted EBITDA RMB2,841.7M |
EV / Sales (TTM) | about 1.0x | TTM revenue RMB16,030.3M |
P/B | about 1.6x | Equity RMB6,513.8M (Jun 2026) |
Dividend yield (trailing 12 months) | about 5.5% | HK$0.16 final FY2025 + HK$0.82 interim 2026 |
Analyst Ratings & Targets
| Broker | Rating | Target price (HKD) | Date |
|---|---|---|---|
CICC | Outperform (maintained) | 17.7 | Apr 2026 |
China Merchants Securities | Strong Buy (maintained) | 21.0 | Apr 2026 |
Soochow Securities | Buy (maintained) | — | Apr 2026 |
Guosheng Securities | Buy (maintained) | — | Apr 2026 |
Huatai Securities | Buy (reiterated) | — | Jul 2026 |
Dividend metric
| Dividend metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim DPS (HKD) | 0.37 | 0.25 | 0.44 | 0.30 | 0.19 |
Final DPS (HKD) | 0.17 | 0.38 | 0.18 | 0.05 | 0.16 |
Total DPS (HKD) | 0.54 | 0.63 | 0.62 | 0.35 | 0.35 |
Payout of adjusted net profit (%) | 30 | 50 | 46 | 38 | 30 |
Credit Ratings
| Agency | Rating | Outlook | Date / note |
|---|---|---|---|
Moody's | Ba3 CFR; senior unsecured B1 (as of 2022) | Positive (from Stable) | Downgraded from Ba2 on 1 Apr 2022; outlook revised Sep 2026 |
S&P Global | BB+ issuer; notes BB (as of Jan 2022) | Stable (2022) | — |
Capital Instruments
| Instrument | Amount | Coupon | Maturity | Notes |
|---|---|---|---|---|
USD term loans (2022 / 2024 facilities) | Bank loans total RMB5,069.5M (current RMB1,308.5M) | Floating (swapped) | 2027 | Being refinanced by the about US$320M facility signed 5 Aug 2026; RMB300M prepaid 13 Aug 2026 |
New term loan + RCF | About US$320M + US$10M | — | Extended (n/d) | Signed 5 Aug 2026 |
Senior notes due 2028 | US$300M (carrying RMB2,098.5M) | 9.125% | Jul 2028 | Issued Jan 2025; early redemption option embedded |
Guaranteed bonds due 2027 | RMB500M (carrying RMB413.6M, all current) | 7.5% | 2027 | Issued 20 Mar 2024 |
MYR Bn bank borrowings | Included in bank loans | Low-cost RMB | Various | Increasing share |
LC discounting (Dec 2025) | RMB244.8M | — | ≤180 days | Working-capital facility |
Analyst Conclusions
Management guidance (H1 2026 interim, 25 Aug 2026)
Management expects "continued growth with consistent underlying full-year profitability despite macro challenges." The specific expectations are:
ANC: continued growth across China, ANZ domestic and expansion markets.
BNC: further IMF growth from HMO IMF, new-mother education and Stage 3 conversion.
PNC: an upward trajectory, with China PNC focused on locally made, high-margin product.
Costs: stepped-up H2 marketing investment.
Balance sheet: continued deleveraging.
There is no numerical guidance.
Consensus growth expectations
Broker commentary (CICC, CMS, Huatai, Soochow, Guosheng; Apr–Jul 2026) uniformly cites:
-
a "new product big year" (HMO IMF, Swisse launches);
-
accelerating deleveraging that lowers interest costs;
-
valuation upside.
Bull case
-
Structural IMF share gains. Biostime's super-premium share rose from 12.4% (2023) to 20.6% (LTM Jun 2026), and Stage 1 / Stage 2 scan growth was +68.8% / +41.8% in H1 2026. This builds a Stage 3 pipeline that extends the IMF recovery into 2027, independent of recall effects.
-
Earnings and deleveraging flywheel. Finance costs fell 46.2% in H1 2026, and net leverage dropped to 2.05x. A Moody's upgrade and the 2027 refinancing could cut interest further, converting more EBITDA into equity value and supporting a 50% payout. The trailing yield is about 5.5% at about 5.7x EV/EBITDA.
-
Swisse franchise compounding. No. 1 positions in China and Australia, a US$1bn brand, Douyin rank rising from No. 4 to No. 3, and expansion markets growing 30%+ give a multi-year mid-to-high-single-digit growth runway at 70% gross margin.
Bear case
-
Recall-driven demand is transitory. Management concedes part of the H1 2026 IMF uplift reflected competitor recalls. As Nestlé, Danone and others restore trust, IMF growth could decelerate sharply against a high 2026 base, while China's IMF market keeps shrinking (−3.5%).
-
H1 margins overstate run-rate. The 21.8% adjusted EBITDA margin benefited from marketing phasing; FY2025's full-year margin was 14.3%. A heavy H2 2026 A&P step-up could disappoint full-year expectations.
-
Tail risks. An adverse Federal Court outcome on the ATO matter (about A$370M+ plus interest versus the A$104M deposit), China CBEC regulatory change, and 74% revenue concentration in China could each impair equity value. Goodwill and intangibles of RMB12.7bn leave little tangible equity cushion.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing |
|---|---|
| Q3 2026 / 9M operating data (IMF growth durability; Swisse China channel mix) | About mid-Oct to Nov 2026 |
| Drawdown of the US$320M refinancing; further term-loan prepayments; Moody's rating action | Q4 2026 – 2027 |
| H2 2026 marketing intensity versus margin; FY2026 results and final dividend | Mar 2027 |
| Super-premium IMF share trajectory (Nielsen) as competitor recalls normalise | Quarterly |
| ATO matter: Federal Court and ART hearing dates; any settlement | 2027 onward |
| Solid Gold China localisation completion; Zesty Paws growth (more than 23,000 doors) | End-2026 |
| China birth-support policies and CBEC regulatory changes | Ongoing |
| RMB500M 7.5% bonds due 2027 repayment / refinancing | 2,027 |
Concluding analyst verdict
H&H enters late 2026 at a genuine inflection after a bruising 2022–2024 period. In those years debt-funded pet M&A, a three-year China IMF re-registration upheaval, rising USD rates and a revolving door at the CEO office combined to drive reported earnings to a loss in FY2024.
The evidence for repair is now strong and mostly verifiable in audited and reviewed filings:
-
revenue growth of +10.0% (FY2025) accelerating to +23.9% (H1 2026);
-
gross margin at 65.4%;
-
finance costs halved;
-
net leverage cut from 3.99x to 2.05x in 18 months;
-
the dividend payout restored to 50%.
The quality of the recovery is mixed but better than sceptics allow. Swisse's leadership in China and Australia, and Zesty Paws' omni-channel scaling, are organic, multi-year achievements. Biostime's share gains began well before the 2026 recalls: share rose from 13.3% to 17.1% during 2025. The recalls amplified, rather than created, the IMF rebound. However, the H1 2026 margin peak is partly a phasing artefact. Investors should anchor on full-year adjusted EBITDA margins in the high-teens rather than above 21%, and expect IMF growth to moderate meaningfully in 2027.
At roughly 5.7x EV/LTM adjusted EBITDA, about 8.4x adjusted P/E and a trailing yield of about 5.5% (dossier estimates at HK$17.95), the market still prices H&H as a levered, China-concentrated consumer name carrying an unresolved A$370M+ tax dispute.
-
controlling-shareholder governance;
-
a rotating-CEO structure without a single accountable leader;
-
negative tangible equity;
-
CBEC regulatory dependency.
On balance, the risk-reward appears constructive. Continued deleveraging toward about 1.5x, a potential Moody's upgrade from Ba3, and sustained Swisse compounding offer equity upside, while a dividend near 50% payout pays investors to wait. The two decisive monitorables are the durability of IMF growth through 2027 and the Federal Court outcome on the ATO dispute. A loss on the latter, without settlement, is the single largest identifiable downside to this view.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / background | Committees |
|---|---|---|---|
Mr. Luo Fei | Chairman, Executive Director | Co-founder (1999); CEO until Mar 2019; standing member of the CEO Office; controlling-shareholder interest of 67.18% | Chair, Nomination Committee |
Mr. Wang Yidong ("Jason Wang") | Executive Director; Group Chief Financial & Operating Officer | Standing member of the CEO Office; holds 0.41% (Dec 2025) | — |
Mrs. Laetitia Albertini (née Garnier) | Non-executive Director | Joined 2010; ED from 26 Mar 2018; CEO 19 Mar 2019 – 31 Dec 2022; NED from 1 Jan 2023 (NED fee RMB800k p.a. per media reports); holds 0.34% | — |
Dr. Zhang Wenhui | Non-executive Director | — | — |
Mr. Luo Yun | Non-executive Director | Co-founder; brother of Luo Fei; associated with the controlling holding structure | Audit Committee member |
Mrs. Mingshu Zhao Wiggins | Non-executive Director | Appointed by 1 Jan 2024 (board list) | — |
Mr. Tan Wee Seng | Independent NED | Long-serving INED | Audit, Nomination |
Mrs. Lok Lau Yin Ching | Independent NED | Long-serving INED | — |
Professor Ding Yuan | Independent NED | Accounting / financial expertise | Chair, Audit Committee |
Executive Leadership Team
| Name | Role | Notes |
|---|---|---|
Akash Bedi | Regional CEO, North America, Europe, India & Middle East; first rotating Group CEO (from 1 Dec 2023) | Former Chief Strategy & Operations Officer; Acting CEO Oct 2022 – Aug 2023; holds 0.26% |
Nicholas (Nick) Mann | Regional CEO, Asia, Australia & New Zealand; second in the rotation | Holds 0.26% |
Li Fengting (Suceka Lee) | Regional CEO, China; third in the rotation | Holds 0.30% |
Zhang Qizhang (Victor Zhang) | Chief People Officer; standing CEO Office member | Holds 0.30% |
Wang Yidong (Jason Wang) | CFO & COO | See board |
Steve Ball | CEO, North America (PNC) / former Zesty Paws CEO | — |
Board & Management Changes
| Date | Change |
|---|---|
26 Sep 2022 | Announced Albertini would cease as CEO on 31 Dec 2022; Bedi named Acting CEO from 1 Oct 2022 |
28 May 2023 | Camillo Pane (ex-CEO of Coty Inc.; previously Reckitt Benckiser Consumer Health) appointed CEO effective 1 Sep 2023 for a three-year term |
20 Nov 2023 | Pane and the company "mutually agreed to separate"; CEO Office with rotating CEO established as a "permanent fixture" |
26 Mar 2024 | Executive Committee dissolved; functions absorbed by the CEO Office |
Major Shareholders
| Holder | Shares | % of issued | Date / source |
|---|---|---|---|
Coliving Holdings Ltd (via Flying Company Ltd / Coliving Ltd; UBS Trustees (BVI) as trustee) — Luo family | 432,000,000 | 66.92 | SDI filing 3 Apr 2025; aktien.guide 10 Apr 2026 |
Luo Fei (aggregate interest incl. above) | 433,678,198 | 67.18 | SDI 3 Apr 2025 |
Templeton Asset Management / Franklin Resources | 31,287,281 | 4.85 | 14 Mar 2025 |
Fidelity International | 13,123,000 | 2.03 | 31 Mar 2026 |
The Vanguard Group | 6,437,988 | 1.00 | Simply Wall St (date n/d) |
Dimensional Fund Advisors | 3,691,000 – 5,094,073 | 0.57 – 0.79 | 30 Apr 2026 / earlier (sources differ) |
E Fund Management | 4,679,000 | 0.72 | 31 Dec 2025 |
Bank of Communications Schroder Fund Mgmt | 4,537,101 | 0.70 | Simply Wall St |
BlackRock | 2,781,522 | 0.43 | Simply Wall St |
Southbound Stock Connect (aggregate, SH + SZ) | about 78–86M | about 12.1 – 13.4 | Lixinger, Jul–Aug 2026 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs H&H |
|---|---|---|
China IMF (super-premium) | Feihe (China Feihe, 6186.HK) | Domestic market leader across tiers; also sourced ARA oil from the Cabio supplier implicated in 2026 |
China IMF | Nestlé (Illuma, Wyeth, NAN) | Global leader; 2026 recall damaged its China position |
China IMF | Danone (Aptamil, Nutrilon) | Premium imported leader; 2026 recalls in some markets |
China IMF | a2 Milk Company | Premium A2-protein niche |
China IMF | Junlebao, Yili (Pro-Kido / Jinlingguan), Mengniu (Reeborne) | Domestic scale players |
China IMF | Abbott, Friesland (Friso) | Imported premium brands |
China / ANZ VHMS | By-health (300146.SZ) | Leading Chinese domestic VHMS company, strong offline / pharmacy |
China / ANZ VHMS | Blackmores (Kirin Holdings) | Australian VHMS rival in ANZ and China CBEC |
China / ANZ VHMS | Haleon (Centrum, Caltrate) | Global multinational VHMS |
China / ANZ VHMS | Amway (Nutrilite) | Direct-selling VHMS leader |
China / ANZ VHMS | Bayer (Elevit, Berocca), Herbs of Gold, Nature's Way, GNC, Move Free (Reckitt) | Category specialists |
Paediatric probiotics | Culturelle (i-Health / DSM-Firmenich), BioGaia, Life-Space, domestic pharmacy brands | H&H (Biostime) is No. 1 in China per Kantar |
US pet supplements | Nutramax (Cosequin, Dasuquin), PetHonesty, Native Pet, Purina (Pro Plan Veterinary Supplements), NaturVet, VetriScience | Zesty Paws No. 1 on Amazon (2023); No. 4 offline (10.0%, 2023) |
US / China pet food | Nestlé Purina, Mars Petcare (Royal Canin), General Mills (Blue Buffalo), Hill's (Colgate), Orijen / Acana (Champion, Mars); China: Myfoodie (Guai Bao), Gambol (Fregate), Royal Canin China | Solid Gold is No. 2 in China online premium cat dry food; small share in the US |
Competitor Detail
| Metric | H&H (FY2025) |
|---|---|
Revenue | RMB14.35bn |
Revenue growth | +10.0% |
Gross margin | 62.4% |
Adjusted EBITDA margin | 14.3% (H1 2026: 21.8%) |
R&D intensity | 1.5% |
Balance sheet | Net leverage 3.45x (2.05x Jun 2026) |
Recent Developments
There were no layoffs, product safety recalls of H&H's own products, or regulatory sanctions against the company in public sources during the window.



